Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma

Cancer

Volumn 80, Issue 3, 1997, Pages 442-453

  Ragde, Haakon ^a,b   Blasko, John C ^a,b   Grimm, Peter D ^c   Kenny, Gerald M ^a,b   Sylvester, John E ^c   Hoak, David C ^d   Landin, Kent ^a   Cavanagh, William ^b  

^a NORTHWEST HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Northwest Neuroscience Institute   (United States)

^d Pathology Associates Inc   (United States)

Author keywords

Biochemical failure; Brachytherapy; Gleason's score; Iodine 125; Prostate carcinoma; Prostate specific antigen progression; Prostate specific antigert; T classification

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BRACHYTHERAPY; CANCER CLASSIFICATION; CANCER SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIOIODINATION;

ADENOCARCINOMA; BIOPSY, NEEDLE; BRACHYTHERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS;

EID: 0030764130     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970801)80:3<442::AID-CNCR12>3.0.CO;2-X     Document Type: Article

References (85)

1. Whitmore WF Jr., Hilaris B, Grabstald H. Retropubic implantation of Iodine-125 in the treatment of prostatic cancer. J Urol 1972;108:918-20.
2. Whitmore WF Jr. Interstitial radiation therapy for carcinoma of the prostate. Prostate 1980;1:157-68.
3. Elkon D, Kim JA, Constable WC. Anatomic localization of radioactive gold seeds of the prostate by computer-aided tomography. Comput Tomogr 1981;5:89-93.
4. Gore RM, Moss AA. Value of computed tomography in interstitial 125-I brachytherapy of prostatic carcinoma. Radiology 1983;146:453-8.
5. Wilson JW, Morales A, Bruce AW, Froud P. Interstitial radiotherapy for localized carcinoma of the prostate. Can J Surg 1983;26:363-5.
6. el-Mahdi AM, Kuban DA, Schellhammer PF. The treatment of choice for localized poorly differentiated adenocarcinoma of the prostate. Am J Clin Oncol 1985;8:477-80.
7. Whitmore WF Jr., Hilaris B, Batata M, Sogani P, Herr H, Morse M. Interstitial radiation: short-term palliation or curative therapy? Urology 1985;25(2 Suppl):24-9.
8. Peschel RE, Fogel TD, Kacinski BM, Kelly K, Mate TP. Iodine-125 implants for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1985;11:1777-81.
9. Giles GM, Brady LW. Iodine implantation after lymphadenectomy in early carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1986;12:2117-25.
10. Kuban DA, el-Mahdi AM, Schellhammer PF. Effect of local tumor control on distant metastases and survival in prostatic adenocarcinoma. Urology 1987;30:420-6.
11. Whitmore WF Jr., Hilaris B, Sogani P, Herr H, Batata M, Fair W. Interstitial radiation using I-125 seeds. Prog Clin Biol Res 1987;243B:177-95.
12. Koprowski CD, Berkenstock KG, Borofski AM, Ziegler JC, Lightfoot DA, Brady LW. External beam irradiation versus 125 Iodine implant in the definitive treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1991;21:955-60.
13. Perez CA, Lee HK, Georgiou A, Lockett MA. Technical factors affecting morbidity in definitive irradiation for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1994; 28:811-9.
14. Leibel SA, Heimann R, Kutcher GJ, Zelefsky MJ, Burman CM, Melian E, et al. Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate: preliminary results of a phase I dose-escalation study. Int J Radiat Oncol Biol Phys 1994;28:55-65.
15. Bagshaw MA, Cox RS, Hancock SL. Control of prostate cancer with radiotherapy: long-term results. J Urol 1994;152(5 Pt 2):1781-5.
16. Murphy GP, Mettlin C, Menck H, Winchester DP, Davidson AM. National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J Urol 1994;152(5 Pt 2):1817-9.
17. Stone NN, Stock RG, DeWyngaert JK, Tabert A. Prostate brachytherapy: improvements in prostate volume measurements and dose distributions using interactive ultrasound-guided implantation and three-dimensional dosimetry. Radiat Oncol Investig 1995;3:185-95.
18. Blasko JC, Grimm P, Ragde H. Brachytherapy and organ preservation in the management of carcinoma of the prostate. Semin Radiat Oncol 1993;3:240-9.
19. Porter AT, Blasko JC, Grimm PD, Reddy SM, Ragde H. Brachytherapy for prostate cancer. CA Cancer J Clin 1995;45: 165-78.
20. Fuks Z, Leibel SA, Wallner KE, Begg CB, Fair WR, Anderson LL, et al. The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125 Iodine implantation. Int J Radiat Oncol Biol Phys 1991;21:537-47.
21. Herr HW. Radioactive seed implantation for carcinoma of the prostate. Urol Surg 1980;7:1-7. In: Ehrlich RM, editor. Modern technics in surgery [series]. Armonk, NY: Futura Publishing Company, 1980.
22. Hilaris BS, Whitmore WF Jr., Batata MA, Barzell W, Tokita N. 125 I implantation of the prostate: dose-response considerations. Front Radiat Ther Oncol 1978;21:82-90.
23. Rao GU, Kan PT, Howells R. Interstitial volume implants with I-125 seeds. Int J Radiat Oncol Biol Phys 1981;7:431-8.
24. Freeman ML, Goldhagen P, Sierra E, Hall EJ. Studies with encapsulated 125 I sources. II. Determination of the relative biological effectiveness using cultured mammalian cells. Int J Radiat Oncol Biol Phys 1982;8:1355-61.
25. Abadir R, Logan KW. Clinical problems associated with dosimetry of 125-Iodine for cancer of the prostate. J Can Assoc Radiol 1984;35:250-3.
26. Watanabe H, Kato H, Kato T, Monta M, Tanaka M. Diagnostic application of the ultrasonotomography of the prostate. Nippon Hinyokika Gakkai Zasshi (Jpn J Urol) 1968;59:273-9. (Jpn.)
27. Holm HH, Juul N, Pedersen JF, Hansen H, Stroyer I. Transperineal Iodine-125 seed implantation in prostate cancer guided by transrectal ultrasonography. J Urol 1983;130:283-6.
28. Blasko JC, Ragde H, Schumacher D. Transperineal percutaneous Iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endocuriether/Hypertherm Oncol 1987;3:131-9.
29. Wallner K, Chiu-Tsao ST, Roy J, Arterbery VE, Whitmore W, Jain S. An improved method for computerized tomography-planned transperineal 125-Iodine prostate implants. J Urol 1991;146:90-5.
30. Ling CC. Permanent implants using Au-198, Pd-103, and I-125: radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys 1992;23:81-7.
31. Ling CC, Li WX, Anderson LL. The relative biological effectiveness of I-125 and Pd-103. Int J Radiat Oncol Biol Phys 1995;32:373-8.
32. Mettlin C, Murphy GP, Lee F, Littrup PJ, Chesley A, Babaian R, et al. Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project. J Urol 1994;152(5 Pt 2):1737-40.
33. Mostofi FK, Murphy GP, Mettlin C, Sesterhenn IA, Batsakis JG, Khaliq SU, et al. Pathology review in an early prostate cancer detection program: results from the American Cancer Society-National Prostate Cancer Detection Project. Prostate 1995;27:7-12.
34. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948-54.
35. Hermanek P, Sobin LH, editors. UICC (Union Internationale Contre le Cancer): TNM classification of malignant tumours. 4th edition. Berlin:Springer-Verlag, 1987:121-6.
36. Ragde H, Blasko JC, Schumacher D. Use of transrectal ultrasound in transperineal Iodine-125 seeding for prostate cancer. Methodology. J Endourol 1989;3:209-18.
37. Brawer MK, Peehl DM, Stamey TA, Bostwick DG. Keratin immunoreactivity in benign and neoplastic human prostate. Cancer Res 1985;45:3663-7.
38. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 1993; 20:713-25.
39. Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC, Billebaud T, Delmas V, Meulemans A, et al. Systematic biopsies accurately predict extracapsular extension of prostate cancer after persistent/recurrent detectable PSA after radical prostatectomy. Urology 1994;44:371-6.
40. Kaplan ID, Cox RS, Bagshaw MA. Prostate-specific antigen after external beam radiotherapy for prostate cancer: follow-up. J Urol 1993;149:519-22.
41. Zagars GK, Pollack A. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome. Urology 1995;45:476-83.
42. Zagars GK. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. Int J Radiat Oncol Biol Phys 1992;23:47-53.
43. Ritter MA, Messing EM, Shanahan TG, Potts S, Chappell RJ, Kinsella TJ. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 1992;10:1208-17.
44. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152(5 Pt 2):1837-42.
45. Bagshaw MA. Comments on the treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome - regarding Zietman et al., IJROBP 1995; 32:287-92 [editorial].
46. Int J Radiat Oncol Biol Phys 1995; 32:541-3.
47. McLaughlin PW, Sandler HM, Jiroutek MR. Prostate-specific antigen following prostate radiotherapy: how low can you go? [editorial]. J Clin Oncol 1996;14:2889-91.
48. Bostwick DG, Egbert BM, Fajardo LF. Radiation injury of the normal and neoplastic prostate. Am J Surg Pathol 1982; 6:541-51.
49. Jacobi GH, Hohenfellner R. Staging, management and post-treatment reevaluation of prostate cancer: dogma questioned. In: Jacobi HC, editor. Prostate cancer. Baltimore: Williams & Wilkins, 1982:31-56.
50. Scardino PT, Wheeler TM. Local control of prostate cancer with radiotherapy: frequency and prognostic significance of positive results of postirradiation prostate biopsy. NCI Monogr 1988;7:95-103.
51. Schellhammer PF, el-Mahdi AM, Higgins EM, Schultheiss TE, Ladaga LE, Babb TJ. Prostate biopsy after definitive treatment by interstitial 125 Iodine implant or external beam radiation therapy. J Urol 1987;137:897-901.
52. Prestidge BR, Hoak DC, Grimm PD, Ragde H, Cavanagh W, Blasko JC. Post-treatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:31-9.
53. Stock RG, Stone NN, DeWyngaert JK, Lavagnini P, Unger PD. Prostate specific antigen findings and biopsy results following interactive ultrasound-guided transperineal brachytherapy for early stage prostate carcinoma. Cancer 1996; 77:2386-92.
54. Blasko JC, Grimm PD, Ragde H. External beam irradiation with Palladium-103 implantation for prostate carcinoma. [Abstract]. Int J Radiat Oncol Biol Phys 1994;30:219.
55. Kaye KW, Olson DJ, Payne JT. Detailed preliminary analysis of 125-Iodine implantation for localized prostate cancer using percutaneous approach. J Urol 1995;153(3 Pt 2):1020-5.
56. Kabalin JN, Hodge KK, McNeal JE, Freiha FS, Stamey TA. Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen. J Urol 1989;142(2 Pt 1):326-72.
57. Scardino PT, Wheeler TM. Prostatic biopsy after irradiation therapy for prostate cancer. Urology 1985;25(2 Suppl):39.
58. Crook JM, Perry GA, Robertson S, Esche BA. Routine prostate biopsy following radiotherapy for prostate cancer: results for 226 patients. Urology 1995;45:624-32.
59. Hilaris B, Fuks Z, Nori D. Interstitial irradiation in prostatic cancer: report of 10-year results. In: Rolf, editor. Interventional radiation therapy techniques/brachytherapy. Berlin: Springer-Verlag, 1991:235.
60. Grado GL, Larson TR, Collins JM, Kriegshauser JS, Balch CS. Fluoroscopic and ultrasound guided prostate implant: technique and experience at Mayo Clinic Scottsdale. In: Meeting Program of the 18th annual meeting of the American Brachy Therapy Society, Scottsdale, Arizona, December 11, 1995:10.
61. Dattoli MJ, Wasserman SG, Koval JM, et al.Conformal brachytherapy boost to external beam irradiation for localized high risk prostate cancer. [Abstract]. Int J Radiat Oncol Biol Phys 1995;32:251.
62. Beyer DC, Priestly JB. Biochemical disease-free survival following I-125 prostate implantation. [Abstract]. Int J Radiat Oncol Biol Phys 1995;32:254.
63. Wallner K, Roy J, Zelefsky M, Fuks Z, Harrison L. Short-term freedom from disease progression after I-125 prostate implantation. Int J Radiat Oncol Biol Phys 1994;30:405-9.
64. Wallner K, Roy J, Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 1995;32:465-71.
65. Schellhammer PF, Jordan GH, el-Mahdi AM. Pelvic complications after interstitial and external beam irradiation of urologic and gynecologic malignancy. World J Surg 1986; 10:259-68.
66. DeLaney TF, Shipley WU, O'Leary MP, Biggs PJ, Prout GR Jr. Preoperative radiation, lymphadenectomy, and 125 Iodine implantation for patients with localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1986;12:1779-85.
67. Fowler JE Jr., Barzell W, Hilaris BS, Whitmore WF Jr. Complications of 125-Iodine implantation and pelvic lymphadenectomy in the treatment of prostate cancer. J Urol 1979;121:447-51.
68. Wallner K, Roy J, Harrison L. Tumor control and morbidity following transperineal Iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 1996;14:449-53.
69. Stone NN, Stock RG. Brachytherapy for prostate cancer: real-time three-dimensional interactive seed implantation. Techniques Urol 1995;1:72-80.
70. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995;154:131-8.
71. Goad JR, Chang SJ, Ohori M, Scardino PT. PSA after definitive radiotherapy for clinically localized prostate cancer. Urol Clin North Am 1993;20:727-36.
72. Hancock SL, Cox RS, Bagshaw MA. Prostate-specific antigen after radiotherapy for prostate cancer: a re-evaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford University. J Urol 1995; 154:1412-7.
73. Hanks GE, Hanlon A, Schultheiss T, Corn B, Shipley WU, Lee WR. Early prostate cancer: the national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group studies with prospects for improvements with conformal radiation and adjuvant androgen deprivation. J Urol 1994;152(5 Pt 2):1775-80.
74. Zagars GK, von Eschenbach AC. Prostate-specific antigen: an important marker for prostate cancer treated by external beam radiation therapy. Cancer 1993;72:538-48.
75. Pisansky TM, Cha SS, Earle JD, Durr ED, Kozelsky TF, Wieand H, et al. Prostate-specific antigen as a pre-therapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 1993;11:2158-66.
76. Frazier HA, Robertson JE, Humphrey PA, Paulson DF. Is prostate-specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J Urol 1993;149:516-8.
77. Zietman AL, Coen JJ, Shipley WU, Willett CG, Efird JT. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate-specific antigen value as a predictor of treatment outcome. J Urol 1994;151:640-5.
78. Cosgrove MD, Kaempf MJ. Prostate cancer revisited. J Urol 1976;115:79-81.
79. Kurth KH, Altwein JE, Skoluda D, Hohenfellner R. Follow-up of irradiated prostatic carcinoma of aspiration biopsy. J Urol 1977;117:615-7.
80. Schellhammer PF, el-Mahdi AM, Higgins EM, Schultheiss TE, Ladaga LE, Babb TJ. Prostate biopsy after definitive treatment by interstitial 125 Iodine implant or external beam radiation therapy. J Urol 1987;137:897-901.
81. Cox JD, Stoffel TJ. The significance of needle biopsy after irradiation for stage C adenocarcinoma of the prostate. Cancer 1977;40:156-60.
82. Kandzari SJ, Riley RS, Belis JA, Jain PR. Postradiation biopsy and histological effects in early stage prostatic cancer treated with Iodine-125 implants. Prostate 1986;9:319-26.
83. Leach GE, Cooper JF, Kagan AR, Snyder R, Forsythe A. Radiotherapy for prostatic carcinoma: post-irradiation prostatic biopsy and recurrence patterns with long-term follow-up. J Urol 1982;128:505-9.
84. Blasko JC, Wallner K, Grimm PD, Ragde H. Prostate specific antigen based disease control following ultrasound guided I 125 implantation for stage T1/T2 prostatic carcinoma. J Urol 1995;154:1096-9.
85. Wallner K, Lee H, Wasserman S, Dattoli M. Low risk of urinary incontinence following prostate brachytherapy in patients with prior transurethral prostate resection. Int J Radiat Oncol Biol Phys. 1997;37:565-9.